Karl Yen

4.5k total citations · 2 hit papers
25 papers, 2.9k citations indexed

About

Karl Yen is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Dermatology. According to data from OpenAlex, Karl Yen has authored 25 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 8 papers in Physiology and 4 papers in Dermatology. Recurrent topics in Karl Yen's work include Cystic Fibrosis Research Advances (11 papers), Asthma and respiratory diseases (8 papers) and Neonatal Respiratory Health Research (5 papers). Karl Yen is often cited by papers focused on Cystic Fibrosis Research Advances (11 papers), Asthma and respiratory diseases (8 papers) and Neonatal Respiratory Health Research (5 papers). Karl Yen collaborates with scholars based in United States, United Kingdom and France. Karl Yen's co-authors include Claudia L. Ordoñez, Jane C. Davies, Sally Rodriguez, Claire Wainwright, J.S. Elborn, Bonnie W. Ramsey, Qunming Dong, Isabelle Sermet‐Gaudelus, Matthias Griese and Steven M. Rowe and has published in prestigious journals such as New England Journal of Medicine, Neurology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Karl Yen

24 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation

2011 1.5k citations Bonnie W. Ramsey, Jane C. Davies et al. New England Journal of Medicine profile →
Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation

2013 369 citations Jane C. Davies, Claire Wainwright et al. American Journal of Respiratory and Critical Care Medicine profile →

Peers

Countries citing papers authored by Karl Yen

Since Specialization

Citations

This map shows the geographic impact of Karl Yen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karl Yen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karl Yen more than expected).

Fields of papers citing papers by Karl Yen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karl Yen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karl Yen. The network helps show where Karl Yen may publish in the future.

Co-authorship network of co-authors of Karl Yen

This figure shows the co-authorship network connecting the top 25 collaborators of Karl Yen. A scholar is included among the top collaborators of Karl Yen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karl Yen. Karl Yen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	62188 Amlitelimab Reduces Th2-, Th1-, and Th17/22-Related Cytokines and Chemokines in Adults With Moderate-to-Severe Atopic Dermatitis): Results From an Exploratory Analysis of the Phase 2b STREAM-AD Study 2025 ·Journal of the American Academy of Dermatology ·Bob Geng, Stephan Weidinger, Saeko Nakajima, Donald Y.M. Leung, Charles Lynde, Karl Yen, Junwen Deng, (unknown), (unknown)	0
2	Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis 2024 ·Journal of Allergy and Clinical Immunology ·Stephan Weidinger, Andrew Blauvelt, Kim Papp, Adam Reich, Chih‐Hung Lee, Margitta Worm, Charles Lynde, Yoko Kataoka, Peter Foley, Xiaodan Wei, Wanling Wong, (unknown), Christine Weber, (unknown), Sonya Davey, Fabrice Hurbin, (unknown), Karl Yen, John T. O’Malley, Charlotte Bernigaud	12
3	Efficacy and Safety of Rilzabrutinib in Pemphigus: PEGASUS Phase 3 Randomized Study 2024 ·Journal of Investigative Dermatology ·Dédée F. Murrell, F. Caux, Aikaterini Patsatsi, Owen Hagino, Lidia Rudnicka, Snejina Vassileva, Soner Uzun, (unknown), Karl Yen, Puneet Arora, Steven G. Gourlay, P. Joly, Victoria P. Werth	7
4	523 - Efficacy and safety of amlitelimab (an anti-OX40 ligand antibody) in patients with moderate-to-severe atopic dermatitis: 24-week results from a phase 2b trial (STREAM-AD) 2024 ·British Journal of Dermatology ·Stephan Weidinger, Andrew Blauvelt, Kim Papp, Adam Reich, Chih‐Hung Lee, Margitta Worm, Charles Lynde, Yoko Kataoka, Peter Foley, Christine Weber, Wanling Wong, Fabrice Hurbin, (unknown), Karl Yen, Xiaodan Wei, John T. O’Malley, Charlotte Bernigaud	6
5	Stride Velocity 95th Centile: Insights into Gaining Regulatory Qualification of the First Wearable-Derived Digital Endpoint for use in Duchenne Muscular Dystrophy Trials 2021 ·Journal of Neuromuscular Diseases ·Laurent Servais, Karl Yen, (unknown), (unknown), David Vissière, (unknown)	37
6	A Phase 1b/2 Study of the Anti-Myostatin Adnectin RG6206 (BMS-986089) in Ambulatory Boys with Duchenne Muscular Dystrophy: A 72-Week Treatment Update (P1.6-062) 2019 ·Neurology ·Kathryn R. Wagner, Brenda Wong, Barry J. Byrne, Cuixia Tian, Leslie K. Jacobsen, Giridhar Tirucherai, Michael Rabbia, Heidemarie Kletzl, Juergen Dukart, Rose Ong, Karl Yen, Gautam Sajeev, James Signorovitch, Susan J. Ward, (unknown), Michelle L. Krishnan	5
7	Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE) 2018 ·Journal of the American Academy of Dermatology ·Eric L. Simpson, Carsten Flohr, Lawrence F. Eichenfield, Thomas Bieber, Howard Sofen, Alain Taı̈eb, Ryan Owen, Wendy S. Putnam, Marcela Castro, Kendra DeBusk, Chin‐Yu Lin, Athina Voulgari, Karl Yen, Theodore A. Omachi	245
8	Nasal Biomarkers Characterization In Lebrikizumab Bronchoscopy Study (CLAVIER) 2018 ·Journal of Allergy and Clinical Immunology ·Fang Cai, Francis Abreu, Han Ting Ding, David F. Choy, (unknown), Tracy Staton, Rich Erickson, Kun Peng, (unknown), Amelia Au‐Yeung, Trevor T. Hansel, Leif Bjermer, Cécile Holweg, Karl Yen, John G. Matthews, Heleen Scheerens	2
9	Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroids 2017 ·Respiratory Medicine ·(unknown), (unknown), И. В. Лещенко, Karl Yen, Cécile Holweg, Judith Anzures‐Cabrera, Carmen Martín, Wendy S. Putnam, Laura Governale, Julie Olsson, John G. Matthews	46
10	Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies 2015 ·Thorax ·Nicola A. Hanania, Michael Noonan, Jonathan Corren, Phillip E. Korenblat, Yanan Zheng, Saloumeh K Fischer, Melissa Cheu, Wendy S. Putnam, Elaine Murray, Heleen Scheerens, Cécile Holweg, Romeo Maciuca, Sarah Gray, Ramona L. Doyle, Dana McClintock, Julie Olsson, John G. Matthews, Karl Yen	299
11	Efficacy and Safety of Lebrikizumab in Severe Uncontrolled Asthma: Results from the Lute and Verse Phase II Randomized, Double-Blind, Placebo-Controlled Trials 2014 ·Journal of Allergy and Clinical Immunology ·Nicola A. Hanania, Michael Noonan, Jonathan Corren, Phillip E. Korenblat, Yanan Zheng, Wendy S. Putnam, Elaine Murray, (unknown), Heleen Scheerens, Romeo Maciuca, Sarah Gray, Ramona L. Doyle, Dana McClintock, John G. Matthews, Karl Yen	18
12	Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a G551D Mutation breakdown → 2013 ·American Journal of Respiratory and Critical Care Medicine ·Jane C. Davies, Claire Wainwright, Gerard J. Canny, Mark Chilvers, Michelle S. Howenstine, À. Munck, Jochen G. Mainz, Sally Rodriguez, Haihong Li, Karl Yen, Claudia L. Ordoñez, Richard C. Ahrens	369
13	Ivacaftor in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation 2012 ·CHEST Journal ·Patrick A. Flume, Theodore G. Liou, Drucy Borowitz, Haihong Li, Karl Yen, Claudia L. Ordoñez, David E. Geller	236
14	WS6.4 Long-term safety and efficacy of ivacaftor in subjects with cystic fibrosis who have the G551D-CFTR Mutation 2012 ·Journal of Cystic Fibrosis ·(unknown), (unknown), Karl Yen, Jane C. Davies	9
15	WS6.5 Ivacaftor in subjects 6 to 11 years of age with cystic fibrosis and the G551D-CFTR mutation 2012 ·Journal of Cystic Fibrosis ·Jane C. Davies, (unknown), Karl Yen, Richard C. Ahrens	8
16	46 Hyperpolarized Gas MRI of ivacaftor therapy in subjects with cystic fibrosis who have the G551D-CFTR mutation 2012 ·Journal of Cystic Fibrosis ·Talissa A. Altes, Mac Johnson, (unknown), John P. Mugler, Lucía Flors, Jaime F. Mata, (unknown), (unknown), Tao Song, Karl Yen, Deborah Froh, Martyn C. Botfield	8
17	43 Patient-reported outcomes in Phase 3 trials of ivacaftor in subjects with CF who have the G551D-CFTR mutation 2012 ·Journal of Cystic Fibrosis ·Alexandra L. Quittner, Bonnie W. Ramsey, (unknown), Karl Yen, J.S. Elborn	5
18	Late-breaking abstract: VX-770, an investigational CFTR potentiator, in subjects with CF and the G551D mutation 2011 ·European Respiratory Journal ·Barry J. Plant, Bonnie W. Ramsey, Karl Yen, Qunming Dong, Sally Rodriguez, J.S. Elborn	1
19	A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation breakdown → 2011 ·New England Journal of Medicine ·Bonnie W. Ramsey, Jane C. Davies, Noel G. McElvaney, Elizabeth Tullis, Scott C. Bell, (unknown), Matthias Griese, Edward F. McKone, Claire Wainwright, Michael W. Konstan, Richard B. Moss, Félix Ratjen, Isabelle Sermet‐Gaudelus, Steven M. Rowe, Qunming Dong, Sally Rodriguez, Karl Yen, Claudia L. Ordoñez, J.S. Elborn	1528
20	61* VX-770 in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation 2011 ·Journal of Cystic Fibrosis ·Patrick A. Flume, Drucy Borowitz, Theodore G. Liou, (unknown), Karl Yen, Claudia L. Ordoñez, David E. Geller	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact